Provectus Biopharmaceuticals, Stock Price - PVCT

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$65.99
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$30.00
SMALL CAP PRO
Monthly Subscription
for only
$43.59
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Provectus Biopharmaceuticals, Inc. (QB) PVCT Other OTC Common Stock Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  -0.0021 -3.95% 0.051 0.0549 0.046 0.054003 0.0531 15:58:58
Bid Price Ask Price Spread Spread % News
0.05 0.0517 0.0017 3.29% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
78 1,381,024 $ 0.0501 $ 69.23k 3.01M 0.01 - 0.08
Last Trade Time Type Quantity Stock Price Currency
16:44:27 seq 5,000 $0.05 USD

Provectus Biopharmaceuticals, Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 18.6M 364.77M $ -24.43M - -0.76 75.81M
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
98.92k 0.03% $ - 0.00% - -

more financials information »

Provectus Biopharmaceuticals, Inc. (QB) News

Historical PVCT Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.03850.06790.03750.0000340k6M3M0.012532.47%
1 Month0.040.06790.0350.0000340k6M2M0.01127.50%
3 Months0.01670.06790.01670.0000340k17M3M0.0343205.39%
6 Months0.05010.06790.0110.0000144k26M4M0.00091.80%
1 Year0.0350.080.0110.0000144k26M3M0.01645.71%
3 Years2.453.410.0110.0000144k26M3M-2.399-97.92%
5 Years0.676.030.0110.00007k31M2M-0.619-92.39%

Provectus Biopharmaceuticals, Inc. (QB) Description

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.